AzurRx BioPharma, Inc. AZRX
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 34.38M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -0.93
- Beta
- 1.51
- Short ratio
- 0.19
- Inst. own
- 5.82%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 15, 2021
- 50-d avg
- 4.94
- 200-d avg
- 7.50
- 1y target
- 16.00
News
5 years ago globenewswire.com
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22 Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22
5 years ago pennystocks.com
3 Penny Stocks That Top Investors Buying Right Now
Which penny stocks are you watching in September 2021? Here's three for some watchlist inspiration The post 3 Penny Stocks That Top Investors Buying Right Now appeared first on Penny Stocks to Buy,…
-
5 years ago benzinga.com
46 Biggest Movers From Yesterday
Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share.
5 years ago zacks.com
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.
-
5 years ago benzinga.com
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results.
5 years ago globenewswire.com
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the…
5 years ago seekingalpha.com
AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
5 years ago benzinga.com
AzurRx BioPharma Announces Reverse Merger With First Wave Bio
AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. First Wave Bio is a clinical-stage…
5 years ago globenewswire.com
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI”
5 years ago globenewswire.com
AzurRx BioPharma Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021 Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021
5 years ago globenewswire.com
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract Phase 2 placebo-controlled clinical trial to confirm…
5 years ago globenewswire.com
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned
5 years ago globenewswire.com
AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis
Proposed Phase 1b/2a clinical trial designed to determine safety and potential efficacy of oral and topical FW-420 Proposed Phase 1b/2a clinical trial designed to determine safety and potential…
5 years ago globenewswire.com
AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies…
5 years ago pennystocks.com
3 Penny Stocks That Top Investors Are Buying Right Now
Top traders are watching these penny stocks right now, here's why The post 3 Penny Stocks That Top Investors Are Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |…
5 years ago zacks.com
AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints
AzurRx (AZRX) is developing lead pipeline candidate as monotherapy and in combination regimen as potential treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis.
5 years ago investorplace.com
AZRX Stock: The Huge Trial News Lifting Little-Known AzurRX BioPharma Today
Today, AZRX stock is making headlines after the company showed some impressive results from a clinical trial of a cystic fibrosis treatment. The post AZRX Stock: The Huge Trial News Lifting…
5 years ago pulse2.com
AzurRx BioPharma Shares Increase Over 40% Pre-Market: Why It Happened
The shares of AzurRx BioPharma, Inc. (NASDAQ: AZRX) increased by over 40% pre-market. This is why it happened.
5 years ago globenewswire.com
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)
BOCA RATON, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies…
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 282 companies set new 52-week lows.
5 years ago globenewswire.com
AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819
BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies…
5 years ago globenewswire.com
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
BOCA RATON, Fla., Aug. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant…
5 years ago pulse2.com
AZRX Stock Price Increases Over 30% Pre-Market: Details You Should Know
The stock price of AzurRx BioPharma Inc (NASDAQ: AZRX) increased by over 30% pre-market. These are some details you should know.
-
7 years ago benzinga.com
Stocks That Fell Through 52-Week Lows Wednesday
Stocks That Fell Through 52-Week Lows Wednesday
-
7 years ago benzinga.com
Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018
Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018
-
7 years ago benzinga.com
Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018
Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018
-
7 years ago benzinga.com
Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018
Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018
-
8 years ago benzinga.com
36 Stocks Moving In Wednesday's Mid-Day Session
36 Stocks Moving In Wednesday's Mid-Day Session
-
8 years ago benzinga.com
Stocks Which Set New 52-Week Low Yesterday, October 11th
Stocks Which Set New 52-Week Low Yesterday, October 11th
-
8 years ago benzinga.com
41 Stocks Moving In Tuesday's Mid-Day Session
41 Stocks Moving In Tuesday's Mid-Day Session
-
8 years ago benzinga.com
30 Stocks Moving In Friday's Mid-Day Session
30 Stocks Moving In Friday's Mid-Day Session